Incidence and patterns of treatment failure in patients among treatment approaches in early-stage FL
| . | RT alone, n = 171 . | Systemic therapy,* n = 60 . | Systemic therapy + maintenance rituximab, n = 49 . | . | |||
|---|---|---|---|---|---|---|---|
| n/N . | % . | n/N . | % . | n/N . | % . | P . | |
| Total relapses | 42/171 | 24.6 | 11/60 | 18.3 | 2/49 | 4.1 | .006 |
| In-field relapse only | 3/171 | 1.7 | 3/60† | 5.0 | 0/49 | 0 | .254 |
| In-field and distant relapse | 4/171 | 2.3 | 2/60 | 3.3 | 0/49 | 0 | |
| Distant relapse only | 35/171 | 20.4 | 6/60 | 10.0 | 2/49 | 4.1 | |
| Transformation | 11/171 | 6.4 | 2/60 | 3.3 | 0/49 | 0 | .145 |
| Lymphoma-related mortality | 6/171 | 3.5 | 2/60 | 3.3 | 2/49 | 4.1 | .694 |
| All-cause mortality | 12 /171 | 7.0 | 3/60 | 5.0 | 2/49 | 4.1 | .976 |
| . | RT alone, n = 171 . | Systemic therapy,* n = 60 . | Systemic therapy + maintenance rituximab, n = 49 . | . | |||
|---|---|---|---|---|---|---|---|
| n/N . | % . | n/N . | % . | n/N . | % . | P . | |
| Total relapses | 42/171 | 24.6 | 11/60 | 18.3 | 2/49 | 4.1 | .006 |
| In-field relapse only | 3/171 | 1.7 | 3/60† | 5.0 | 0/49 | 0 | .254 |
| In-field and distant relapse | 4/171 | 2.3 | 2/60 | 3.3 | 0/49 | 0 | |
| Distant relapse only | 35/171 | 20.4 | 6/60 | 10.0 | 2/49 | 4.1 | |
| Transformation | 11/171 | 6.4 | 2/60 | 3.3 | 0/49 | 0 | .145 |
| Lymphoma-related mortality | 6/171 | 3.5 | 2/60 | 3.3 | 2/49 | 4.1 | .694 |
| All-cause mortality | 12 /171 | 7.0 | 3/60 | 5.0 | 2/49 | 4.1 | .976 |